Department of Gastroenterology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Department of Gastroenterology, Fourth Military Medical University, Xi'an, China.
J Gastroenterol Hepatol. 2021 Mar;36(3):637-645. doi: 10.1111/jgh.15185. Epub 2020 Jul 29.
Inflammatory bowel disease (IBD) has increased in incidence and prevalence in Asian countries since the end of the 20th century. Moreover, differences in the cause, phenotypes, and natural history of IBD between the East and West have been recognized. Therefore, the Asian Organization for Crohn's and Colitis and the Asia Pacific Association of Gastroenterology have established recommendations on medical management of IBD in Asia. Initially, the committee members drafted 40 recommendations, which were then assessed according to Grading of Recommendations Assessment, Development and Evaluation. Eight statements were rejected as this indicated that consensus had not been reached. The recommendations encompass pretreatment evaluation; medical management of active IBD; medical management of IBD in remission; management of IBD during the periconception period and pregnancy; surveillance strategies for colitis-associated cancer; monitoring side effects of thiopurines and methotrexate; and infections in IBD.
炎症性肠病(IBD)自 20 世纪末以来在亚洲国家的发病率和患病率都有所增加。此外,东西方之间的 IBD 的病因、表型和自然史存在差异已得到认可。因此,亚洲克罗恩病和结肠炎组织以及亚太胃肠病学会已经制定了亚洲 IBD 医学管理的建议。最初,委员会成员起草了 40 条建议,然后根据推荐评估、制定和评估的分级进行评估。有 8 项声明被拒绝,因为这表明尚未达成共识。这些建议包括治疗前评估;活动期 IBD 的药物治疗;缓解期 IBD 的药物治疗;围孕期和妊娠期 IBD 的管理;结肠炎相关癌症的监测策略;硫唑嘌呤和甲氨蝶呤的副作用监测;以及 IBD 中的感染。